Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances

Series type: Risk assessments

Summary

This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 5F-MDMB-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • Europol–EMCDDA Joint Report on 5F-MDMB-PINACA (methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate) — a summary
  • Risk Assessment Report on a new psychoactive substance: methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA)
  • Technical report on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA)
  • Participants of the risk assessment meeting, 7-8 November 2017
Cover of the risk assessment
Pages: 
64
Price: 
free
ISBN: 
978-92-9497-314-6
ISSN: 
1725-4493
Pub. DOI: 
10.2810/868403
Catalog Number: 
TD-AK-18-006-EN-N
Loading